Oregon seeks $900 million from insulin makers and PBMs over pricing

By ··2 min read

Oregon Attorney General Dan Rayfield has filed a $900 million lawsuit against Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark and Optum, alleging a coordinated scheme to inflate insulin and diabetes drug prices. The 173-page complaint was filed in Multnomah County Circuit Court.

Oregon Attorney General Dan Rayfield filed a lawsuit on January 7, 2026, seeking $900 million in damages from the country's largest insulin manufacturers and pharmacy benefit managers, alleging they coordinated to artificially inflate the prices of insulin and other diabetes medications. The 173-page complaint, filed in Multnomah County Circuit Court, names manufacturers Novo Nordisk, Sanofi and Eli Lilly and PBMs Express Scripts, CVS Caremark and Optum. The state is also seeking a court order halting the alleged scheme and restitution for consumers.

The complaint alleges that the manufacturers raised list prices to secure favourable placement on PBM formularies and then paid substantial rebates and fees back to the PBMs, so that higher list prices generated larger rebates and greater profits for both sides. It further alleges that the companies deliberately kept lower-cost insulin products off formularies, denying patients access to cheaper treatments. The attorney general's office says insulin costs around $2 to manufacture and was priced at about $20 in the United States in the late 1990s, and that diabetes drug prices have risen sharply over the past 15 years even as production costs fell. The claims arise under Oregon's Unlawful Trade Practices Act.

The attorney general's announcement did not include responses from the defendants.

Rayfield described the case as the first in a series of actions on prescription drug pricing and said his office is examining the role of PBMs and other supply chain entities. The lawsuit adds Oregon to a growing number of states pursuing the insulin pricing theory, alongside Missouri and Iowa. It follows federal measures that have already reduced some patient costs, including the Inflation Reduction Act's $35 monthly insulin co-pay cap for Medicare beneficiaries and list price cuts announced by manufacturers in 2023. The FTC's parallel administrative case against the same three PBMs, filed in 2024, rests on a similar theory of rebate-driven formulary exclusion.

The case is at an early stage in Multnomah County Circuit Court. No trial date had been reported, and the attorney general's office said further enforcement actions on drug pricing should be expected.

Cite this report

The Precedent. "Oregon seeks $900 million from insulin makers and PBMs over pricing." August 29, 2026. https://theprecedent.org/article/oregon-seeks-900-million-from-insulin-makers-and-pbms-over-pricing